产品中心
-
产品货号
产品名称
规格
销售价
会员价
货期
产地
订购
-
C926
Recombinant Human CEACAM7/Carcinoembryonic antigen CGM2
10ug
1200
1080
现货
国产
-
C926
Recombinant Human CEACAM7/Carcinoembryonic antigen CGM2
50ug
3520
3168
现货
国产
-
C926
Recombinant Human CEACAM7/Carcinoembryonic antigen CGM2
500ug
12320
11088
现货
国产
-
C926
Recombinant Human CEACAM7/Carcinoembryonic antigen CGM2
1mg
17600
15840
现货
国产
- 产品简介
- 使用说明
- 相关产品
- 参考文献
- 购买咨询
Catalog# C926 Source Human Cells Description Recombinant Human Carcinoembryonic Antigen-Related Cell Adhesion Molecule 7/CEACAM7 is produced by our mammalian expression system in human cells. The target protein is expressed with sequence (Thr36-Phe142) of Human CEACAM7 fused with a polyhistidine tag at the C-terminus. Names Carcinoembryonic Antigen-Related Cell Adhesion Molecule 7, Carcinoembryonic Antigen CGM2, CEACAM7, CGM2 Accession # Q14002 Formulation Lyophilized from a 0.2 μm filtered solution of 20mM PB,150mM NaCl,pH7.4 Shipping The product is shipped at ambient temperature. Reconstitution Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100 μg/ml.
Dissolve the lyophilized protein in 1X PBS.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles.Storage Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.
Reconstituted protein solution can be stored at 4-7°C for 2-7 days.
Aliquots of reconstituted samples are stable at < -20°C for 3 months.Purity Greater than 95% as determined by SEC-HPLC and reducing SDS-PAGE. Endotoxin Less than 0.1 ng/µg (1 IEU/µg). Amino Acid Sequence TNIDVVPFNVAEGKEVLLVVHNESQNLYGYNWYKGERVHANYRIIGYVKNISQENAPGPAHNGRE TIYPNGTLLIQNVTHNDAGIYTLHVIKENLVNEEVTRQFYVFVDHHHHHHBackground Carcinoembryonic Antigen-Related Cell Adhesion Molecule 7 (CEACAM7) is a member of the immunoglobulin superfamily A and CEA family. CEACAM7 localizes to the cell membrane and contains one Ig-like C2-type domain and one Ig-like V-type domain. The expression of CEACAM7 is significantly decreased in rectal cancer. Differences in CEACAM7 expression levels between long-term survivors and those with recurrent disease introduce a potential tumor marker to define a subset of patients who benefit most from adjuvant therapy.